Link between inherited gene variation and high-risk pediatric leukemia, greater risk of relapse
10/22/2013
Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome. The study appears in the online edition of the scientific journal Nature Genetics. The high-risk variant was found in the GATA3 gene...
Overcoming crizotinib resistance in lung cancers
10/22/2013
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics...
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented...
Researcher says Skid Row cancer study has implications for treatment today
10/22/2013
An ethically dubious medical research study from the 1950s and 60s, known as the "Bowery series," foreshadowed and shared commonalities with prostate cancer screening and treatment measures as they are carried out today, argues University of Pennsylvania physician and historian Robert Aronowitz in two new publications...
One of the challenges of understanding cancer is trying to determine the mechanisms that drive metastasis, or the process by which tumor cells are able to spread throughout the body. In order to investigate metastasis, researchers at The Wistar Institute focused on a process involving the phenotypes - the outward, physical appearance based on genetic coding - of tumor cells...
Link between inherited gene variation and high-risk pediatric leukemia, greater risk of relapse
10/22/2013
Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome. The study appears in the online edition of the scientific journal Nature Genetics. The high-risk variant was found in the GATA3 gene...
Overcoming crizotinib resistance in lung cancers
10/22/2013
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics...
Clarified role of signal-relay proteins may help explain spread of cancer
10/22/2013
Cell biologists at The Johns Hopkins University have teased apart two integral components of the machinery that causes cells to move. Their discovery shows that cellular projections, which act as hands to help a cell "crawl," are apparently always initiated by a network of message-relaying proteins inside the cell...
Targeting the common cancer protein KRAS
10/22/2013
Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex, according to results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23...
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented...